August 02, 2021
Article
The app will deliver up-to-the-minute glucose data in patients using Freestyle Libre 2 glucose sensors.
July 29, 2021
The FDA noted the extent of the treatment effect of tenapanor is of unclear clinical significance, despite evidence of efficacy.
Higher microbiome α diversity had an association with less T2D and lower insulin resistance in individuals without diabetes.
July 24, 2021
Video
Harold Bays, MD discussed the effectiveness of GLP-1 RA in treatment, as well as the development of oral semaglutide.
July 21, 2021
Data show while women with GDM wanted to be responsible for their own health, an annual reminder and combined appointments would help to screen for T2D.
July 09, 2021
Data show SGLT2is reduced HHF in patients with both stablished HFrEF and CKD and are likely to also be effective in patients with HFpEF.
July 06, 2021
FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.
July 02, 2021
Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.
July 01, 2021
Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.
June 30, 2021
Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.
